Leukemia research · 2026
Clinical use and adverse effects of tyrosine kinase inhibitors in patients with chronic myeloid leukemia: The role of comorbidities.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kır Selin, Abdullayeva Nigar, Yılmazer Ali, Saydam Güray, Hekimgil Mine, Demirci Zühal, Soyer Nur
Аннотация
OBJECTIVE: Chronic myeloid leukemia (CML) is frequently accompanied by comorbidities that may influence the tolerability of tyrosine kinase inhibitors (TKIs). This study aimed to evaluate TKI-related adverse effects and their association with comorbidities in patients with CML.
MATERIALS AND METHODS: This retrospective study analyzed clinical data from 102 patients with chronic-phase CML who were diagnosed between 1997 and 2023 and followed at a single outpatient clinic.
RESULTS: Among the 102 patients, the most common comorbidities were hypertension, diabetes mellitus, coronary artery disease, hypothyroidism, hyperlipidemia, chronic kidney disease, and chronic obstructive pulmonary disease. Hypothyroidism was significantly associated with the development of adverse effects in patients receiving first-line imatinib therapy (p = 0.037). In system-based analyses, adverse effects were more frequently observed in imatinib-treated patients with oncological comorbidities compared with those without (p = 0.031). Additionally, adverse effects were significantly less frequent in patients treated with imatinib than in those receiving other TKIs (p = 0.048). When all TKIs were evaluated together, cardiovascular comorbidities were the only system significantly associated with an increased risk of adverse effects (p = 0.015).
CONCLUSION: Comorbidities, particularly hypothyroidism and cardiovascular diseases, significantly influence the development of TKI-related adverse effects in patients with CML. Careful assessment of comorbidities and concomitant medications is essential for optimal TKI selection and toxicity management in clinical practice.
MATERIALS AND METHODS: This retrospective study analyzed clinical data from 102 patients with chronic-phase CML who were diagnosed between 1997 and 2023 and followed at a single outpatient clinic.
RESULTS: Among the 102 patients, the most common comorbidities were hypertension, diabetes mellitus, coronary artery disease, hypothyroidism, hyperlipidemia, chronic kidney disease, and chronic obstructive pulmonary disease. Hypothyroidism was significantly associated with the development of adverse effects in patients receiving first-line imatinib therapy (p = 0.037). In system-based analyses, adverse effects were more frequently observed in imatinib-treated patients with oncological comorbidities compared with those without (p = 0.031). Additionally, adverse effects were significantly less frequent in patients treated with imatinib than in those receiving other TKIs (p = 0.048). When all TKIs were evaluated together, cardiovascular comorbidities were the only system significantly associated with an increased risk of adverse effects (p = 0.015).
CONCLUSION: Comorbidities, particularly hypothyroidism and cardiovascular diseases, significantly influence the development of TKI-related adverse effects in patients with CML. Careful assessment of comorbidities and concomitant medications is essential for optimal TKI selection and toxicity management in clinical practice.